Stockscreener 앱 받기
32.14
0.66%
0.21
시장 영업 전:
31.88
-0.26
-0.81%
전일 마감가:
$31.93
열려 있는:
$32.12
하루 거래량:
1.65M
Relative Volume:
0.57
시가총액:
$3.71B
수익:
-
순이익/손실:
$-237.39M
주가수익비율:
-15.17
EPS:
-2.1183
순현금흐름:
$-224.58M
1주 성능:
-2.96%
1개월 성능:
+8.73%
6개월 성능:
+21.15%
1년 성능:
+14.42%
1일 변동 폭
$31.66
$32.63
1주일 범위
$31.39
$33.96
52주 변동 폭
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
32.14 | 3.69B | 0 | -237.39M | -224.58M | -2.1183 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook - Finviz
VKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring A 178% Upside Potential - DirectorsTalk Interviews
Viking Therapeutics (VKTX) Stock: Financial Performance Highlights 22% Revenue Growth and 44% Profit Increase in 2025 - MEXC
Viking Therapeutics, Inc. (VKTX) Stock: Revenue Surges 22% as Adjusted Net Income Jumps 44% in 2025 - MEXC
Rafferty Asset Management LLC Purchases 41,888 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Getting Closer To Key Technical Benchmark - Investor's Business Daily
Vanguard Group Reduces Stake in Viking Therapeutics - National Today
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
Viking Therapeutics, Inc. $VKTX Shares Sold by Vanguard Group Inc. - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Upgraded at BTIG Research - MarketBeat
Viking Therapeutics (VKTX) Is Up 9.1% After Advancing VK2735 As Rival Obesity Drug Stumbles - simplywall.st
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today - Yahoo Finance
Viking Therapeutics: The High-Stakes Weight Loss Contender - MarketBeat
Viking Therapeutics Advances VK2735 As Obesity Data And Valuation Draw Focus - simplywall.st
Viking Therapeutics Gains Ground Amid Novo Nordisk's Clinical Setback - AD HOC NEWS
Is Viking Therapeutics (VKTX) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - The Motley Fool
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - 富途牛牛
Viking Therapeutics Advances VK2735 As Phase 3 Trials Shape Valuation - simplywall.st
Viking Therapeutics Gains Momentum as Rival Stumbles - AD HOC NEWS
Viking Therapeutics Shares Surge as Rival Stumbles in Obesity Drug Race - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Investor Outlook: A 169% Upside Potential Sparks Interest - DirectorsTalk Interviews
Viking Therapeutics, Inc. (VKTX): A bull case theory - MSN
Viking Therapeutics Stock Jumps 11% After Obesity Drug Update: Analysts See $93 Target - TIKR.com
Viking Therapeutics Gains Momentum in Competitive Weight-Loss Drug Arena - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Bitget
The Ultimate Biotech Stock to Buy With $500 Right Now - AOL.com
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. - The Globe and Mail
Viking Therapeutics Targets Expansion Amid Market Challenges - timothysykes.com
Viking Therapeutics Stock Gains Amid Obesity Drug Buzz - Benzinga
Viking Therapeutics (VKTX) Valuation In Focus As VK2735 Advances In GLP 1 Weight Loss Trials - simplywall.st
Why Viking Therapeutics Stock Is Climbing Again - TipRanks
Why Viking Therapeutics Stock Is Up More Than 9% Today - Yahoo Finance
Viking Therapeutics (VKTX) Sees Significant 10.7% Share Price In - GuruFocus
Viking Therapeutics Stock (VKTX) Opinions on Novo Nordisk CagriSema Setback - Quiver Quantitative
Viking Therapeutics Shares Surge as Rival's Obesity Drug Stumbles - AD HOC NEWS
Viking Therapeutics: VK2735 Promise Meets Execution Risk - AlphaStreet News
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds - Nasdaq
Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate - AOL.com
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN
Viking Therapeutics Surges as Obesity Drug Hopes Rise - TipRanks
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. - AOL.com
Viking Therapeutics (NASDAQ:VKTX) Stock Rating Upgraded by Zacks Research - MarketBeat
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity - MSN
Can Viking Therapeutics Really Soar 300%? Why Wall Street Is Betting Big on This Biotech Stock - NAI500
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street - AOL.com
Is Viking Therapeutics Stock Really Going to $125? - AOL.com
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
$100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):